Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

New York State Psychiatric Institute15 enrolled

Overview

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

In order to improve treatment outcome for cannabis use disorder (CUD), the investigators have developed a laboratory model to investigate the effects of potential treatment medications on cannabis withdrawal and on the subjective and reinforcing effects of cannabis in non treatment-seeking cannabis smokers. In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Cannabis Use

Interventions

LorcaserinDRUG

Lorcaserin 10mg BID

PlaceboDRUG

Placebo capsule BID

MarijuanaDRUG

Smoked marijuana cigarette

Eligibility

Sex: ALLMin age: 21 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Current cannabis use * Able to give informed consent and perform study procedures * Women practicing an effective form of birth control * English speaking Exclusion Criteria: * Presence of any clinically significant medical diagnoses * History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes * Current parole or probation * Certain psychiatric diagnoses * Current pregnancy or lactation

Locations (1)

New York State Psychiatric Institute

New York, New York, United States

Outcomes

Primary Outcomes

Cannabis Self-administration

Number of cannabis puffs participant chooses to smoke.

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.